Piroxicam and Cisplatin Show Promise Against Mesothelioma Cells

Piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), has shown anti-tumoral activity against mesothelioma cells and those effects appear to be enhanced when combined with cisplatin.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed for the treatment of a variety of cancers. Their properties include analgesic and antipyretic effects with anti-inflammatory properties in high doses. They are most often used to treat pain, fever and inflammation with two of the most common NSAIDs being aspirin and ibuprofen.

Researchers studied the effects of piroxicam and cisplatin on two mesothelioma cell lines. The cells were treated with each drug as an individual agent and in the second phase, the treatments were combined.

The results indicate that cell growth was significantly limited in both lines and treatment with either agent appeared to disrupt cell cycle phase distribution and expression of some regulatory proteins.

Their effects were significantly increased when used as a combination therapy. In one of the cell lines they appeared to create a synergistic effect on apoptosis (likely through the activation of caspase 8,9).

Piroxicam is currently used in veterinary medicine for the treatment of bladder, colon and prostate cancers and is manufactured by Pfizer under the name "feldene"

The data suggests that a combination of piroxicam and cisplatin should warrant further investigation because of their effect on apoptosis and cell cycles.

News

Resources

This site complies with the HONcode standard for trustworthy health information: verify here

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376